---
title: "RemeGen Wins Fourth NMPA Approval for Disitamab Vedotin in HER2-Low Breast Cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280153935.md"
description: "RemeGen Wins Fourth NMPA Approval for Disitamab Vedotin in HER2-Low Breast Cancer"
datetime: "2026-03-23T11:38:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280153935.md)
  - [en](https://longbridge.com/en/news/280153935.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280153935.md)
---

# RemeGen Wins Fourth NMPA Approval for Disitamab Vedotin in HER2-Low Breast Cancer

RemeGen Wins Fourth NMPA Approval for Disitamab Vedotin in HER2-Low Breast Cancer

### Related Stocks

- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [688331.CN](https://longbridge.com/en/quote/688331.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [09995.HK](https://longbridge.com/en/quote/09995.HK.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)

## Related News & Research

- [RemeGen Forecasts Major Profit Turnaround on Surging Drug Sales and AbbVie Licensing Deal](https://longbridge.com/en/news/294974949.md)
- [Alphamab Starts Phase III Trial of Next-Gen HER2 Drug in High-Risk Breast Cancer](https://longbridge.com/en/news/280228645.md)
- [RemeGen Co. Ltd. Class H (9995) Gets a Buy from CMBC International](https://longbridge.com/en/news/294572671.md)
- [22:20 ETHenlius informa sus resultados de 2025: Crecimiento sostenido tanto en ingresos como en beneficios](https://longbridge.com/en/news/280085895.md)
- [06:47 ETKelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis](https://longbridge.com/en/news/278376120.md)